



Exercise of options, PDMR transaction and TVR

July 7, 2021

RNS Number : 3722E

Renalytix PLC

07 July 2021

Renalytix plc ("Renalytix" or the "Company")

Exercise of options, PDMR transaction and TVR

NEW YORK, 7 July, 2021 - The Board of [Renalytix plc](#) (LSE: RENX) announces that it has issued and allotted 27,500 ordinary shares of 0.25 pence each in the share capital of the Company (the "Option Shares") following an exercise of options on 6 July 2021. The exercise price was 121 pence per Ordinary Share.

Included in the exercise of the Option Shares were options over 15,000 ordinary shares held by Chirag Parikh, a Non-Executive Director/PDMR of the Company. Immediately following the option exercise Mr Parikh also sold an identical number of shares at a price of £10.00 per share.

Application has been made to the London Stock Exchange for the Option Shares to be admitted to trading on AIM. It is expected that admission of the 27,500 new Ordinary Shares to trading on AIM will become effective on, or around, 9 July 2021 ("Admission").

Total voting rights

Following Admission, the Company will have 72,224,786 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 72,224,786.

For further information, please contact:

Renalytix plc
James McCullough, CEO

www.renalytix.com
Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker)
Alex Price / Nicholas Moore

Tel: 020 7710 7600

Investec Bank plc (Joint Broker)
Gary Clarence / Daniel Adams

Tel: 020 7597 4000

Walbrook PR Limited
Paul McManus / Lianne Cawthorne

Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 / 07584 391 303

About Kidney Disease

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and one out of two people with very low kidney function who are not on dialysis do not know they have CKD.¹ Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year, kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

¹ <https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html>

About KidneyIntelX

KidneyIntelX, is a first-of-kind, bioprognostic™ platform that employs a proprietary artificial intelligence-enabled algorithm to combine diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Chirag Parikh
2	Reason for the notification	
a)	Position/status	Non-executive Director
b)	Initial notification /Amendment	Initial Notification

3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Renalytix plc					
b)	LEI	213800NTOH3FK3WER551					
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument	Ordinary shares of £0.0025 each					
	Identification code	GB00BYWL4Y04					
b)	Nature of the transaction	Exercise of options					
c)	Currency	GBP					
d)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£1.21</td><td>15,000</td></tr></table>		Price(s)	Volume(s)	£1.21	15,000
Price(s)	Volume(s)						
£1.21	15,000						
e)	Aggregated information						

	- Aggregated volume	15,000
	- Price	£18,161
f)	Date of the transaction	6 July 2021
g)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Chirag Parikh
2	Reason for the notification	
a)	Position/status	Non-executive Director
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	

a)	Name	Renalytix plc				
b)	LEI	213800NTOH3FK3WER551				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument	Ordinary shares of £0.0025 each				
	Identification code	GB00BYWL4Y04				
b)	Nature of the transaction	Sale of shares				
c)	Currency	GBP				
d)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£10.00</td><td>15,000</td></tr></table>	Price(s)	Volume(s)	£10.00	15,000
Price(s)	Volume(s)					
£10.00	15,000					
e)	Aggregated information					

	- Aggregated volume	15,000
	- Price	£150,000
f)	Date of the transaction	6 July 2021
g)	Place of the transaction	London Stock Exchange

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the potential benefits of repeat testing with KidneyIntelX, the potential for KidneyIntelX to receive regulatory approval from the FDA, the commercial prospects of KidneyIntelX, if approved, including whether KidneyIntelX will be successfully adopted by physicians and distributed and marketed, our expectations regarding reimbursement decisions and the ability of KidneyIntelX to curtail costs of chronic and end-stage kidney disease, optimize care delivery and improve patient outcomes. Words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "seeks," and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have only recently commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the Securities and Exchange Commission (SEC), including the "Risk Factors" section of our annual report on Form 20-F filed with the SEC on October 28, 2020, and other filings we make with the SEC from time to time. All information in this press release is as of the date of the release, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVRUPUUUMUPGGBQ